Vident Investment Advisory’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Vident Investment Advisory’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-20,526	Closed	-$1.83M	–	989
2018 Q1	$1.83M	Buy	20,526 +5,483	+36%	+$414K	0.07%	321
2017 Q4	$1.26M	Buy	15,043 +4,078	+37%	+$400K	0.06%	338
2017 Q3	$1.27M	Buy	10,965 +333	+3%	+$35K	0.07%	335
2017 Q2	$1.24M	Buy	10,632 +4,973	+88%	+$617K	0.1%	299
2017 Q1	$698K	Buy	5,659 +943	+20%	+$124K	0.07%	327
2016 Q4	$642K	Sell	4,716 -607	-11%	-$108K	0.08%	324
2016 Q3	$1.06M	Sell	5,323 -84	-2%	-$14.5K	0.14%	270
2016 Q2	$701K	Sell	5,407 -2,167	-29%	-$241K	0.1%	317
2016 Q1	$708	Buy	7,574 +3,534	+87%	+$385K	0.04%	362
2015 Q4	$819K	Buy	+4,040	New	+$723K	0.1%	328

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vident Investment Advisory's BLCM Position: Q2 2018 in Review

Vident Investment Advisory sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2018, closing a stake of 20,526 shares — an estimated $1.83M sold.

Vident Investment Advisory first reported a position in BLCM in Q4 2015 and held it in 10 quarters. The position peaked at $1.83M in Q1 2018. 96 funds tracked by Wall St. Rank hold BLCM as of Q2 2018.

Vident Investment Advisory reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Vident Investment Advisory sold 20,526 Bellicum Pharmaceuticals, Inc. shares in Q2 2018, an estimated $1.83M.
Vident Investment Advisory first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2015 and held it in 10 quarters.
Vident Investment Advisory's Bellicum Pharmaceuticals, Inc. position peaked at $1.83M in Q1 2018.
96 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2018.

Based on Vident Investment Advisory's 13F filing for Q2 2018, filed 14 Aug 2018.